# Sermorelin + Ipamorelin

> Combination — not ranked · Combos · reviewed 2026-11-08
> Source page: https://peptidemeta.com/p/sermorelin-ipamorelin/

## Quick answers

**What is Sermorelin + Ipamorelin?**

A well-tolerated GH secretagogue blend pairing the bioidentical GHRH fragment Sermorelin with the selective GHRP Ipamorelin for balanced growth hormone stimulation. Sermorelin (GHRH 1-29) plus ipamorelin.

**What is in Sermorelin + Ipamorelin?**

Sermorelin + Ipamorelin typically combines Sermorelin and Ipamorelin. Commercial products vary.

**How strong is the evidence for Sermorelin + Ipamorelin?**

It is not ranked. A PubMed search found no published studies of this combination; only reviews mention it. Sermorelin was once FDA-approved (Geref, since discontinued); ipamorelin has small human pharmacology studies.

**Is Sermorelin + Ipamorelin FDA-approved?**

No. Sermorelin + Ipamorelin is not an approved product; no regulator has reviewed the combination.

**Is Sermorelin + Ipamorelin banned in sport?**

Yes. Sermorelin + Ipamorelin is prohibited in sport by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics).

**How does Sermorelin + Ipamorelin work?**

This blend combines sermorelin (bioidentical GHRH 1-29 acting via the GHRH receptor/cAMP pathway) with ipamorelin (selective ghrelin receptor agonist acting via IP3/PKC). The dual-pathway synergy amplifies GH pulses while both components maintain selectivity: sermorelin preserves feedback physiology and ipamorelin avoids cortisol/prolactin elevation.

**What is known about the safety of Sermorelin + Ipamorelin?**

Both components have established clinical safety histories. Sermorelin was previously FDA-approved (Geref).

## Key facts

- **Evidence tier:** not ranked
- **FDA:** not approved
- **WADA:** prohibited (S2)
- **Peptide:** yes
- **Routes studied:** Subcutaneous, Intramuscular
- **Components:** Sermorelin, Ipamorelin

## Overview

A well-tolerated GH secretagogue blend pairing the bioidentical GHRH fragment Sermorelin with the selective GHRP Ipamorelin for balanced growth hormone stimulation.

## Mechanism

This blend combines sermorelin (bioidentical GHRH 1-29 acting via the GHRH receptor/cAMP pathway) with ipamorelin (selective ghrelin receptor agonist acting via IP3/PKC). The dual-pathway synergy amplifies GH pulses while both components maintain selectivity: sermorelin preserves feedback physiology and ipamorelin avoids cortisol/prolactin elevation.

## Effects reported in research

_Reported outcomes, not promises; see the evidence tier._

- Balanced GH elevation via dual pathways
- Improved sleep quality and recovery
- Enhanced fat metabolism
- Minimal side effects due to selectivity

## Safety & unknowns

Both components have established clinical safety histories. Sermorelin was previously FDA-approved (Geref). Ipamorelin has Phase II data. Combined profile expected to be very well-tolerated. Common side effects: headache, flushing, injection site irritation. Not FDA-approved as a combination.

## Studies

- Vittone J, Blackman MR, Busby-Whitehead J, et al. (1997). *Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men*. Metabolism. Clinical trial. https://pubmed.ncbi.nlm.nih.gov/9005976/
  Six-week study of nightly GHRH 1-29 (the sermorelin sequence) in 11 elderly men: some muscle-strength measures improved, with no change in body composition or metabolic measures.
- Raun K, Hansen BS, Johansen NL, et al. (1998). *Ipamorelin, the first selective growth hormone secretagogue*. European Journal of Endocrinology. Preclinical. https://pubmed.ncbi.nlm.nih.gov/9849822/
  Rat and swine study on the ipamorelin component showing selective GH release without increases in ACTH or cortisol.

## Status sources

- [Drugs@FDA — NDA 019863 Geref (sermorelin acetate), discontinued](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863)
- [Gobburu et al. 1999 — ipamorelin PK/PD in human volunteers](https://pubmed.ncbi.nlm.nih.gov/10496658/)
- [WADA 2026 Prohibited List — S2.2.4 names sermorelin and ipamorelin](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf)

---

Educational reference only — not medical advice. No dosing information is published. Tiers rate the strength of published evidence, not effectiveness or safety.